Making risky decisions to take drug: Effects of cocaine abstinence in cocaine users.


Journal

Pharmacology, biochemistry, and behavior
ISSN: 1873-5177
Titre abrégé: Pharmacol Biochem Behav
Pays: United States
ID NLM: 0367050

Informations de publication

Date de publication:
02 2019
Historique:
received: 03 07 2018
revised: 20 12 2018
accepted: 21 12 2018
pubmed: 26 12 2018
medline: 1 1 2020
entrez: 26 12 2018
Statut: ppublish

Résumé

Risky decision-making is characteristic of drug users, but little is known about the effects of circumstances, such as abstinence, on risky choice behavior in human drug users. We hypothesized that cocaine users would make more risky choices for cocaine (defined as taking a chance to receive a large number of cocaine doses as opposed to choosing to receive a fixed amount of cocaine) after 3 or 7 days of cocaine abstinence, compared to 1 day of cocaine abstinence. Six male nontreatment-seeking current cocaine smokers were enrolled in a 21-day inpatient within-subject study. Participants repeatedly smoked six 25 mg doses of cocaine during a training session and were instructed that they would be making decisions about smoking this dose throughout the study. After 1, 3 and 7 days of cocaine abstinence, participants completed a computerized task in which they repeatedly decided between receiving a guaranteed number of cocaine doses (between 1 and 5; fixed option) or receiving a chance (0.13 to 0.75) to smoke a larger number of cocaine doses (probabilistic option). After completing the computerized task, one of the participants' choices was randomly implemented and they smoked either the fixed number of cocaine doses or had the specified chance to smoke the greater number of doses. Contrary to our hypothesis, 5 of the 6 participants made fewer risky choices after 3 and 7 days of cocaine abstinence compared to one day of abstinence suggesting greater risk-aversion. Thus, even during cocaine abstinence cocaine users make rational decisions related to their drug use.

Identifiants

pubmed: 30584902
pii: S0091-3057(18)30343-5
doi: 10.1016/j.pbb.2018.12.008
pmc: PMC7059600
mid: NIHMS1566517
pii:
doi:

Substances chimiques

Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-26

Subventions

Organisme : NIDA NIH HHS
ID : K05 DA031749
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA021319
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024156
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

PLoS One. 2010 Jun 16;5(6):e11090
pubmed: 20585383
Drug Alcohol Depend. 2005 Feb 14;77(2):169-75
pubmed: 15664718
Pharmacol Biochem Behav. 2008 Sep;90(3):331-8
pubmed: 18445506
Psychol Bull. 2016 May;142(5):546-67
pubmed: 26653865
J Exp Psychol Anim Behav Process. 2005 Oct;31(4):487-92
pubmed: 16248735
Science. 2004 Aug 13;305(5686):1017-9
pubmed: 15310907
Psychol Rev. 2012 Jan;119(1):114-9
pubmed: 22022832
Psychopharmacology (Berl). 1999 Oct;146(4):348-61
pubmed: 10550486
Psychopharmacology (Berl). 2014 Oct;231(21):4179-87
pubmed: 24728653
EMBO Rep. 2013 Jun;14(6):505-8
pubmed: 23681445
Addict Biol. 2009 Jan;14(1):22-31
pubmed: 18855805
Addict Behav. 2016 Jul;58:104-9
pubmed: 26922157
PLoS One. 2013;8(1):e53978
pubmed: 23358126
Pharmacol Biochem Behav. 2016 Nov - Dec;150-151:8-13
pubmed: 27592732
J Exp Psychol Anim Behav Process. 2006 Jul;32(3):295-306
pubmed: 16834496
Q J Exp Psychol B. 2002 Oct;55(4):331-48
pubmed: 12350285
Ann N Y Acad Sci. 2014 Oct;1327:1-26
pubmed: 24654857
Addict Behav. 2014 Nov;39(11):1632-9
pubmed: 24864028
J Gambl Stud. 2003 Spring;19(1):23-51
pubmed: 12635539
Behav Neurosci. 2003 Oct;117(5):927-38
pubmed: 14570543

Auteurs

Richard W Foltin (RW)

Division on Substance Use Disorders, New York State Psychiatric Institute, Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA. Electronic address: rwf2@cumc.columbia.edu.

Suzette M Evans (SM)

Division on Substance Use Disorders, New York State Psychiatric Institute, Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.

Margaret Haney (M)

Division on Substance Use Disorders, New York State Psychiatric Institute, Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.

Kenneth Carpenter (K)

Division on Substance Use Disorders, New York State Psychiatric Institute, Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.

Gillinder Bedi (G)

Melbourne University, Orygen National Centre of Excellence in Youth Mental Health, 35 Poplar Road, Parkville, Victoria 3052, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH